DDX3X and breast carcinoma: Additionally, TRIM58 decreased DDX3 expression by mediating the ubiquitination of DDX3, the downstream effector of the P53/P21 pathway, thereby inducing doxorubicin resistance in breast cancer (Wang et al., 2022).